Aster DM Healthcare announced the convening of shareholder and creditor meetings on March 10, 2026, to approve the Scheme of Amalgamation with Quality Care India Limited. The merger aims to create one of the top 3 hospital chains in India. The company confirmed strong shareholder support, noting a 99.998% approval for the preceding Share Swap. Key governance details regarding promoter rights and board committees are summarized.
Key Update on Amalgamation Scheme
Aster DM Healthcare Limited has provided an update regarding the proposed Scheme of Amalgamation with Quality Care India Limited, as previously disclosed on February 4, 2026. The Company is proceeding to seek necessary approvals from shareholders and creditors via meetings convened under the Companies Act, 2013.
The management emphasizes that the proposed merger is set to establish one of the top 3 hospital chains in India and represents the largest transaction in the Indian hospital sector. Shareholder confidence is high, evidenced by the 99.998% approval received for the related Share Swap mechanism.
Shareholder Meeting Details
The meeting for equity shareholders to consider and approve the Scheme of Amalgamation (via Video Conferencing/OAVM) is scheduled for Tuesday, March 10, 2026, at 10:00 am (IST). The remote e-voting window is set from Friday, March 6, 2026 (9:00 a.m. IST) until Monday, March 9, 2026 (5:00 p.m. IST).
Rationale and Value Creation Factors
The merger is projected to drive long-term shareholder value creation through several factors:
- Creation of one of the top 3 hospital chains with a strong footprint in South and Central India.
- Diversified presence across 9 states and 25 cities with minimal operational overlap.
- A holistic platform featuring 6,690+ clinicians serving approximately 2.0 mm patients quarterly across Hospitals, Clinics, Labs, and Pharmacies.
- Expected EBITDA upside potential of 10-15% (calculated as a percentage of FY24 pro-forma EBITDA).
Governance and Promoter Commitments
To ensure alignment, the scheme grants customary rights to the promoters, Aster Promoters and Blackstone. In adherence to high corporate governance standards, both groups have committed to critical waivers:
- Director Nomination Rights: These rights will diminish proportionally to falling shareholding. Both groups have agreed to waive their right to nominate 3 directors each if their shareholding falls to 10% or below.
- Committee Nomination Rights: Aster Promoters and Blackstone are committed to waive the exercise of nomination rights on Board committees post-effectiveness of the scheme.
- Check-and-Balance: A mechanism is built in where any committee unable to reach a majority decision will have the matter referred directly to the Board for resolution.
The Company asserts that the merger aligns with the long-term interests of all stakeholders by ensuring reasonableness in valuation and robust governance tied to continued commitment (“skin in the game”).
Source: BSE
